A Phase III Study of Brentuximab Vedotin to Treat Newly Diagnosed Hodgkin Lymphoma in Children and Adolescents


Full Title

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults (NCI)


Brentuximab vedotin is approved for treating Hodgkin lymphoma in adults. In this study, researchers are assessing its use to treat Hodgkin lymphoma in children and adolescents when given in combination with standard chemotherapy drugs. Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer.

In this study, patients will be randomly assigned to receive standard chemotherapy with six drugs OR five of the standard chemotherapy drugs plus brentuximab vedotin. Some patients will also receive radiation therapy directed to areas of the body that have a high risk of cancer relapse.

Brentuximab and the standard anticancer drugs being used in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is for patients who are at least 2 years old and no older than 18 years.
  • Patients must be newly diagnosed with high-risk classical Hodgkin lymphoma.

For more information about this study and to inquire about eligibility, please contact Dr. Christopher Forlenza at 212-639-5226.





Disease Status

Newly Diagnosed